History

2010’s

2019

  • Safety study of 6’-Sialyllactose sodium salt in human
  • Changed GeneChem’s Corporate Identity (CI)
  • Filing of US FDA GRAS notice for 6’-Sialyllactose sodium salt

2018

  • Received US FDA GRAS status for 3’-Sialyllactose sodium salt (GRN766)

2017

  • Completion of Self-affirmed GRAS evaluation for 3’-Sialyllactose sodium salt and 6’-Sialyllactose sodium salt in the USA
  • Registration for Cosmetics Manufacturing and Sales Business
  • Acquired the GLP toxicology study data for 6’-Sialyllactose sodium salt
  • Acquired Intellectual Property (IP) management Certification
  • Acquired ISO 9001:2015 Certification

2015

  • Acquired INNOBIZ Company Certification

2014

  • Signed contract for domestic exclusive supply rights with LG Household & Healthcare Co. Ltd. for AquaGG®

2013

  • Jinju branch established

2010

  • Acquired the GLP toxicology study data for 3’-Sialyllactose sodium salt
  • Safety study of 3’-Sialyllactose sodium salt in human
2000’s

2009

  • Completed development of pilot scale production process for 3’- & 6’-Sialyllactose

2007

  • Launched 3’-Sialyllactose for laboratory research

2005

  • α-gal Epitopes for xenotransplantation succeeded for the first time in Korea

2004

  • Successful development and launch of Cy-fluorescent dye for diagnostic DNA microarray chip

2000

  • Technology transfer of location specific gene targeting technology (SGTA™)
  • Central Research Laboratory established
1990’s

1997

  • GeneChem Inc. established